Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference
Trevi Therapeutics將在ATS 2024會議上公佈Haduvio治療慢性咳嗽的第二階段結果
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
Trevi Therapeutics, Inc.（納斯達克股票代碼：TRVI）是一家處於臨床階段的生物製藥公司，該公司正在開發用於治療特發性肺纖維化（IPF）和難治性慢性咳嗽（RCC）的研究性療法Haduvio（口服納布啡ER），今天宣佈，CANAL二期試驗的數據將在2024年美國胸科學會（ATS）國際會議上公佈會議將於5月17日至22日在加利福尼亞州聖地亞哥舉行。演講將於5月19日舉行。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。